CN104958753B - Hig2和urlc表位肽及包含它们的疫苗 - Google Patents

Hig2和urlc表位肽及包含它们的疫苗 Download PDF

Info

Publication number
CN104958753B
CN104958753B CN201510236002.5A CN201510236002A CN104958753B CN 104958753 B CN104958753 B CN 104958753B CN 201510236002 A CN201510236002 A CN 201510236002A CN 104958753 B CN104958753 B CN 104958753B
Authority
CN
China
Prior art keywords
peptide
hla
cancer
ctl
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510236002.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104958753A (zh
Inventor
角田卓也
大泽龙司
吉村祥子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN104958753A publication Critical patent/CN104958753A/zh
Application granted granted Critical
Publication of CN104958753B publication Critical patent/CN104958753B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201510236002.5A 2008-08-19 2009-08-14 Hig2和urlc表位肽及包含它们的疫苗 Active CN104958753B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8997208P 2008-08-19 2008-08-19
US61/089,972 2008-08-19
CN200980141320.6A CN102186491B (zh) 2008-08-19 2009-08-14 Hig2和urlc表位肽及包含它们的疫苗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200980141320.6A Division CN102186491B (zh) 2008-08-19 2009-08-14 Hig2和urlc表位肽及包含它们的疫苗

Publications (2)

Publication Number Publication Date
CN104958753A CN104958753A (zh) 2015-10-07
CN104958753B true CN104958753B (zh) 2018-09-25

Family

ID=41707003

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980141320.6A Active CN102186491B (zh) 2008-08-19 2009-08-14 Hig2和urlc表位肽及包含它们的疫苗
CN201510236002.5A Active CN104958753B (zh) 2008-08-19 2009-08-14 Hig2和urlc表位肽及包含它们的疫苗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN200980141320.6A Active CN102186491B (zh) 2008-08-19 2009-08-14 Hig2和urlc表位肽及包含它们的疫苗

Country Status (16)

Country Link
US (1) US9119800B2 (cg-RX-API-DMAC7.html)
EP (1) EP2328600B9 (cg-RX-API-DMAC7.html)
JP (1) JP5633025B2 (cg-RX-API-DMAC7.html)
KR (1) KR101713581B1 (cg-RX-API-DMAC7.html)
CN (2) CN102186491B (cg-RX-API-DMAC7.html)
AU (1) AU2009283763B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917391A2 (cg-RX-API-DMAC7.html)
CA (1) CA2734467C (cg-RX-API-DMAC7.html)
DK (1) DK2328600T3 (cg-RX-API-DMAC7.html)
ES (1) ES2566011T3 (cg-RX-API-DMAC7.html)
IL (1) IL211117A (cg-RX-API-DMAC7.html)
MX (2) MX337756B (cg-RX-API-DMAC7.html)
RU (1) RU2529373C2 (cg-RX-API-DMAC7.html)
SG (2) SG193806A1 (cg-RX-API-DMAC7.html)
TW (2) TWI580431B (cg-RX-API-DMAC7.html)
WO (1) WO2010021112A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
RS57630B1 (sr) * 2010-11-17 2018-11-30 Aduro Biotech Inc Metode i sastavi za uzrokovanje imunog odgovora na egfrviii
EP2872531A4 (en) 2012-07-10 2016-04-06 Oncotherapy Science Inc LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
SG11201700838VA (en) * 2014-08-04 2017-03-30 Oncotherapy Science Inc Urlc10-derived peptide and vaccine containing same
PL3335725T3 (pl) 2015-08-10 2024-07-22 Toray Industries, Inc. Epitopy PDS5A jako induktory odporności
WO2017026503A1 (ja) 2015-08-12 2017-02-16 オンコセラピー・サイエンス株式会社 Ｄｅｐｄｃ１由来ペプチドおよびそれを含むワクチン
CN110741016A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 嵌合抗体/t-细胞受体构筑体及其用途
LT3538645T (lt) 2017-06-20 2021-04-26 Institut Curie Suv39h1 atžvilgiu defektyvios imuninės ląstelės
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006090810A2 (en) * 2005-02-25 2006-08-31 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
CN1882698A (zh) * 2003-08-20 2006-12-20 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
WO2007029778A1 (ja) * 2005-09-07 2007-03-15 Nec Corporation Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
JP2007246451A (ja) * 2006-03-16 2007-09-27 Keio Gijuku 癌ワクチン

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
WO2001011044A1 (fr) * 1999-08-05 2001-02-15 Kyogo Itoh Antigene de tumeur
AU7748200A (en) 1999-09-30 2001-04-30 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
WO2002030268A2 (en) 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20080286313A1 (en) 2004-06-21 2008-11-20 Kyogo Itoh Peptide Vaccines for the Treatment of Cancers
WO2006085684A2 (en) 2005-02-10 2006-08-17 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
EP1854473A1 (en) 2005-03-03 2007-11-14 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
EP1907580A2 (en) 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
US8053557B2 (en) 2006-06-16 2011-11-08 Onco Therapy Science, Inc. SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
US20100291091A1 (en) 2007-07-30 2010-11-18 ONCOTHERAPY SCIENCE ,inc. Cancer associated gene ly6k
TW201000115A (en) 2008-06-11 2010-01-01 Oncotherapy Science Inc IQGAP3 epitope peptides and vaccines containing the same
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882698A (zh) * 2003-08-20 2006-12-20 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
WO2006090810A2 (en) * 2005-02-25 2006-08-31 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
WO2007029778A1 (ja) * 2005-09-07 2007-03-15 Nec Corporation Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
JP2007246451A (ja) * 2006-03-16 2007-09-27 Keio Gijuku 癌ワクチン

Also Published As

Publication number Publication date
MX2011001883A (es) 2011-03-29
EP2328600A1 (en) 2011-06-08
AU2009283763B2 (en) 2014-06-19
RU2011110376A (ru) 2012-09-27
MX337756B (es) 2016-03-17
IL211117A (en) 2017-03-30
AU2009283763A1 (en) 2010-02-25
EP2328600B9 (en) 2016-07-13
AU2009283763A2 (en) 2011-07-07
SG10201610206VA (en) 2017-01-27
JP2012500184A (ja) 2012-01-05
HK1157204A1 (zh) 2012-06-29
DK2328600T3 (en) 2016-03-29
CN102186491B (zh) 2015-06-10
MX355054B (es) 2018-04-03
US20110243973A1 (en) 2011-10-06
TWI580431B (zh) 2017-05-01
TWI543767B (zh) 2016-08-01
EP2328600A4 (en) 2013-03-06
WO2010021112A1 (en) 2010-02-25
KR101713581B1 (ko) 2017-03-08
KR20110045052A (ko) 2011-05-03
CN104958753A (zh) 2015-10-07
TW201019952A (en) 2010-06-01
US9119800B2 (en) 2015-09-01
CA2734467C (en) 2017-10-03
RU2529373C2 (ru) 2014-09-27
CA2734467A1 (en) 2010-02-25
SG193806A1 (en) 2013-10-30
ES2566011T3 (es) 2016-04-08
CN102186491A (zh) 2011-09-14
EP2328600B1 (en) 2016-01-27
IL211117A0 (en) 2011-04-28
TW201500055A (zh) 2015-01-01
BRPI0917391A2 (pt) 2015-12-01
JP5633025B2 (ja) 2014-12-03

Similar Documents

Publication Publication Date Title
CN104958753B (zh) Hig2和urlc表位肽及包含它们的疫苗
CN102786582B (zh) Tem8肽和包含tem8肽的疫苗
CN102119171B (zh) Cdca1表位肽及包含它的疫苗
MX2011001880A (es) Peptidos de epitope inhbb y vacunas que contienen los mismos.
CN105601725B (zh) Neil3肽及包含它的疫苗
CN102405285A (zh) Foxm1肽及包含它的疫苗
TWI441648B (zh) Ｆｏｘｐ３胜肽疫苗
CN102119170A (zh) Mybl2表位肽及包含它的疫苗
US20140199335A1 (en) C1orf59 peptides and vaccines including the same
CN104086625A (zh) Rab6kifl/kif20a表位肽及包含它的疫苗
US9745343B2 (en) Method of inducing an immune response by administering WDRPUH epitope peptides
HK1157204B (en) Hig2 and urlc10 epitope peptide and vaccines containing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant